期刊论文详细信息
Journal of Bone Oncology | |
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review | |
关键词: Osteonecrosis of the jaw; Zoledronic acid; Bone loss; Aromatase inhibitor; Early breast cancer; | |
DOI : 10.1016/j.jbo.2015.09.001 | |
来源: DOAJ |
【 摘 要 】
Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of developing ONJ when zoledronic acid is used biyearly varies between 0.12% and 0.7%.【 授权许可】
Unknown